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Ravindra L Mehta, John A Kellum, Sudhir V Shah, Bruce A Molitoris, Claudio Ronco, David G Warnock, Adeera Levin and Michael Joannidis Lippi and Guidi suggest using the MDRD estimated GFR as a criterion for diagnosing and staging AKI [1] . The MDRD estimated GFR was derived from patients with chronic kidney disease who were at steady state (age <70 years; average GFR, 40 ml/min/1.73 m 2 ) and had renal functional changes over several months and years [2] .
In contrast to chronic kidney disease, patients with AKI have rapidly changing levels of serum creatinine over a period of days. Consequently, estimated GFR measurements do not represent the nonsteady-state conditions inherent in AKI and are not recommended in hospitalized patients [3] . Secondly, the estimated GFR is derived from serum creatinine, and changes in the opposite direction -that is, when serum creatinine doubles, the estimated GFR is reduced by half. Using a relative change in serum creatinine is therefore easier, without the need for an additional step to compute the estimated GFR. Creatinine and urine output are markers of severity in AKI, and have been validated as important risk predictors for outcome [4, 5] , but do not directly correspond to kidney function at any given time point.
We concur with Lippi and Guidi that more sensitive, accurate and predictive indicators of the measured GFR, injury and prognosis are needed in AKI. Until such markers are validated and widely available, however, the use of the MDRD estimated GFR for the diagnosis and staging of AKI does not provide any additional information to measured changes in serum creatinine.
